Colossal Biosciences: Pioneering De-Extinction and Securing New Funding
Colossal Biosciences, a startup focused on de-extinction, has garnered significant attention since its announcement last year regarding plans to resurrect the dire wolf using genetic material extracted from fossils. While this ambitious project has sparked debate, the company is simultaneously developing valuable technologies that many believe justify its current valuation of $10.2 billion.
Recent reports indicate that Colossal is in discussions to secure additional funding, potentially raising its valuation to between $20 billion and $30 billion. However, details about the investors leading this funding round and the specific amount the company aims to raise remain unclear. What is noteworthy is that Colossal has begun generating revenue over the past year, signaling positive growth for the five-year-old enterprise.
Ben Lamm, co-founder and CEO of Colossal, previously outlined three potential revenue streams for the company. One of these avenues includes offering conservation technology to governmental bodies, such as the U.S. government and the United Arab Emirates (UAE). Recently, the UAE invested $60 million in Colossal, highlighting the growing interest in the company’s innovative approaches to conservation.
In addition to its main initiatives, Colossal has launched three spin-off companies. These include Breaking, which focuses on plastic breakdown technologies; Form Bio, a computational biology platform that has successfully raised $30 million; and Astromech, an AI-driven predictive modeling firm valued at approximately $2 billion as of March. Each of these ventures aims to address pressing environmental and biological challenges.
Lamm has also mentioned plans to develop artificial animal womb technology, which could extend beyond de-extinction applications and potentially assist in human fertility treatments. This technology is anticipated to be ready for implementation by next year, according to Lamm’s statements.
Looking ahead, if Colossal succeeds in reintroducing extinct species like the woolly mammoth and the dodo bird into their original habitats, the company may explore generating revenue through biodiversity credits. This market-based mechanism, akin to carbon credits, would provide a financial incentive for conservation efforts.
The ongoing fundraising efforts align with a broader trend in the technology sector, particularly in areas related to longevity, alternative energy, and deep-tech innovations. As the demand for sustainable solutions continues to rise, Colossal’s initiatives may play a pivotal role in shaping the future of biodiversity and conservation.
As of now, Colossal Biosciences has not responded to requests for further comment regarding its latest funding activities. The company’s journey underscores the intersection of cutting-edge science and environmental stewardship, making it a compelling player in the evolving landscape of biotechnology.
